Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 23.5.2022 | EN | Official Journal of the European Union | C 207/52 |

---

Action brought on 4 April 2022 — Novartis v EUIPO — AstraZeneca (BREZTREV)

(Case T-174/22)

(2022/C 207/69)

Language in which the application was lodged: English

Parties

Applicant: Novartis AG (Basel, Switzerland) (represented by: A. Nordemann-Schiffel, lawyer)

Defendant: European Union Intellectual Property Office (EUIPO)

Other party to the proceedings before the Board of Appeal: AstraZeneca AB (Södertälje, Sweden)

Details of the proceedings before EUIPO

Applicant of the trade mark at issue: Other party to the proceedings before the Board of Appeal

Trade mark at issue: Application for European Union word mark BREZTREV — Application for registration No 18 088 373

Procedure before EUIPO: Opposition proceedings

Contested decision: Decision of the Second Board of Appeal of EUIPO of 21 January 2022 in Case R 738/2021-2

Form of order sought

The applicant claims that the Court should:

|  |  |
| --- | --- |
| — | annul the contested decision; |

|  |  |
| --- | --- |
| — | order EUIPO to pay the costs. |

Plea in law

|  |  |
| --- | --- |
| — | Infringement of Article 8(1)(b) of Regulation (EU) 2017/1001 of the European Parliament and of the Council. |

---

[Top](#document1)